Preclinical studies have demonstrated BCMA- and T cell-dependent anti-tumor activity in vitro and in xenografts models of MM and lymphoma (136) and is currently under evaluation for further development and commercialization. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.